Iovance Biotherapeutics, based in San Carlos, California, specializes in cell therapies for cancer, focusing on its lead product, Amtagvi, for melanoma treatment. The company employs 557 people and went public in 2008.
IOVA filed a patent for "methods and compositions for t-cell coculture potency assays and use with cell therapy products" on Fri, May 17, 2024. The patent was officially published on Thu, October 3, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
